A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Public ClinicalTrials.gov record NCT02122913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists.
Study identification
- NCT ID
- NCT02122913
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2014
- Primary completion
- Jan 31, 2017
- Completion
- Apr 8, 2021
- Last update posted
- Feb 4, 2026
2014 – 2021
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Mass General Cancer Center | Boston | Massachusetts | 02114 | — |
| UH Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| OHSU Hospital - Neurology | Portland | Oregon | 97239 | — |
| Hospital of the University of Pennsylvania - Radiology | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Mercy - Oncology | Pittsburgh | Pennsylvania | 15219 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02122913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2026 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02122913 live on ClinicalTrials.gov.